SKIP TO CONTENT
30+/SKIN
← ACTIVESRECORD A-06FAMILY AVERMECTIN — ANTIPARASITIC AND ANTI-INFLAMMATORY

Ivermectin

Ivermectin

The strongest single-agent evidence base in this register: two trials, 1,371 subjects, and 519 people followed for about a year.

THE TRIALLED STRENGTH, IN THE RANGE WE HAVE SEEN0.88% ——— 1%
1%

The marker is the strength the trials were actually run at. The bar is the span this register has recorded, approved and compounded together. Anything below the marker is a dose nobody has tested; anything above it is an assumption about a dose–response curve nobody has drawn.

IDENTITY & RATINGSA
INCIIvermectin
FAMILYAvermectin — antiparasitic and anti-inflammatory
MOL. WEIGHT875.10 g/mol
REFERENCE CONC.1%
RANGE SEEN0.88 – 1%
STATUSPRESCRIPTION ONLY
ACTS ATEPIDERMIS
ONSET4–12 WK
STABILITYSTABLE
TRIALS ON FILE2
IRRITATION INDEX2 / 10
STRATUM CORNEUM▸ EPIDERMISDERMIS

The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.

01

Mechanism

EVIDENCE GRADE A

Reduces Demodex density and moderates the inflammatory response to it, with independent anti-inflammatory activity on the innate immune pathways implicated in rosacea.

HOUSE NOTES

  • Adverse reactions were reported in 1% or fewer of subjects treated for at least three months — the lowest reaction profile in this register, on skin that is intolerant by definition.
  • The safety cohort runs to 519 subjects at approximately one year. Every compounded rosacea product here is sold as an indefinite subscription with no long-term data at all.
  • It treats papules and pustules. Nothing in it addresses persistent erythema or telangiectasia.
  • Found compounded at 0.88% — 88% of the strength that produced these results, with nothing published about what the other 12% was worth.

MEASURED ENDPOINTS

IGA clear or almost clear+26.8%
12 WKREF-05
Inflammatory lesion reduction+22.3%
12 WKREF-06

SUPPORTING RECORDS

  • REF-05A

    Randomised, vehicle-controlled, co-primary endpoints

    N=683 · 12 WK · DOUBLE-BLIND

  • REF-06A

    Randomised, vehicle-controlled, co-primary endpoints

    N=688 · 12 WK · DOUBLE-BLIND

02

Layering

CONFLICTS & PAIRINGS
DO NOT LAYER
  • Eyes and mucous membranes
PAIRS WITH
03

Reviewed in

3 REVIEWS
EVERY FIGURE HERE RESOLVES TO A RECORD IN THE EVIDENCE REGISTER. NOT MEDICAL ADVICE.
PREVIOUS — A-05Azelaic AcidNEXT — A-07Metronidazole
THE DRAW · NO. 01

Win a year of
prescription skincare

One reader gets a 12 months CoreAge Rx derm plan — the compounded, physician-reviewed subscription we take apart in the register. Worth $780. Leave an address and you are entered.

PRIZE
12 MONTHS OF COREAGE RX
VALUE
$780 — $64.99/MO × 12
ENTRY
ONE EMAIL ADDRESS

VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.

DEPTH 000%
THE DRAW · ONE READER

Win a year of
prescription skincare

One reader gets a 12 months CoreAge Rx derm subscription — compounded, physician-reviewed, delivered. The plan we score in the register.

VALUE$780
TERM12 MONTHS$64.99/MO × 12

VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.